APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiation Toxicity Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Radiation Toxicity Therapeutics Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchRadiation Toxicity Therapeutics Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiation Toxicity Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Radiation Toxicity Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiation Toxicity Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiation Toxicity Therapeutics Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Radiation Toxicity Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Radiation Toxicity Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radiation Toxicity Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radiation Toxicity Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Radiation Toxicity Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Radiation Toxicity Therapeutics market include Coherus BioSciences, Jubilant Life Sciences, Mission Pharmacal Company, Partner Therapeutics, Recipharm AB, Siegfried Holdings, Viatris, Amgen and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Radiation Toxicity Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radiation Toxicity Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiation Toxicity Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Radiation Toxicity Therapeutics market.

Radiation Toxicity Therapeutics Segment by Company

Coherus BioSciences

Jubilant Life Sciences

Mission Pharmacal Company

Partner Therapeutics

Recipharm AB

Siegfried Holdings

Viatris

Amgen

Novartis

Radiation Toxicity Therapeutics Segment by Type

Ionizing Radiation

Non-ionizing Radiation

Radiation Toxicity Therapeutics Segment by Application

Hospital

Research & Academic Institutes

Radiation Toxicity Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Radiation Toxicity Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Radiation Toxicity Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Radiation Toxicity Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Radiation Toxicity Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Radiation Toxicity Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Radiation Toxicity Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiation Toxicity Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiation Toxicity Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiation Toxicity Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiation Toxicity Therapeutics industry.

Chapter 3: Detailed analysis of Radiation Toxicity Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Radiation Toxicity Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Radiation Toxicity Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Radiation Toxicity Therapeutics Industry Trends Table 2. Radiation Toxicity Therapeutics Industry Drivers Table 3. Radiation Toxicity Therapeutics Industry Opportunities and Challenges Table 4. Radiation Toxicity Therapeutics Industry Restraints Table 5. Global Radiation Toxicity Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Radiation Toxicity Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Radiation Toxicity Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Radiation Toxicity Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Radiation Toxicity Therapeutics Company, Product Type & Application Table 10. Global Radiation Toxicity Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Radiation Toxicity Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ionizing Radiation Table 15. Significant Companies of Non-ionizing Radiation Table 16. Global Radiation Toxicity Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Radiation Toxicity Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Radiation Toxicity Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Radiation Toxicity Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Radiation Toxicity Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Research & Academic Institutes Table 23. Global Radiation Toxicity Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Radiation Toxicity Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Radiation Toxicity Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Radiation Toxicity Therapeutics Sales Value Share by Application (2021-2026) Table 27. Global Radiation Toxicity Therapeutics Sales Value Share by Application (2027-2032) Table 28. Global Radiation Toxicity Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Radiation Toxicity Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Radiation Toxicity Therapeutics Sales Value Share by Region (2021-2026) Table 31. Global Radiation Toxicity Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Radiation Toxicity Therapeutics Sales Value Share by Region (2027-2032) Table 33. Global Radiation Toxicity Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Radiation Toxicity Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Radiation Toxicity Therapeutics Sales Value Market Share by Country (2021-2026) Table 36. Global Radiation Toxicity Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Radiation Toxicity Therapeutics Sales Value Market Share by Country (2027-2032) Table 38. Coherus BioSciences Company Information Table 39. Coherus BioSciences Business Overview Table 40. Coherus BioSciences Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Coherus BioSciences Radiation Toxicity Therapeutics Product Portfolio Table 42. Coherus BioSciences Recent Development Table 43. Jubilant Life Sciences Company Information Table 44. Jubilant Life Sciences Business Overview Table 45. Jubilant Life Sciences Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Jubilant Life Sciences Radiation Toxicity Therapeutics Product Portfolio Table 47. Jubilant Life Sciences Recent Development Table 48. Mission Pharmacal Company Company Information Table 49. Mission Pharmacal Company Business Overview Table 50. Mission Pharmacal Company Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Mission Pharmacal Company Radiation Toxicity Therapeutics Product Portfolio Table 52. Mission Pharmacal Company Recent Development Table 53. Partner Therapeutics Company Information Table 54. Partner Therapeutics Business Overview Table 55. Partner Therapeutics Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Partner Therapeutics Radiation Toxicity Therapeutics Product Portfolio Table 57. Partner Therapeutics Recent Development Table 58. Recipharm AB Company Information Table 59. Recipharm AB Business Overview Table 60. Recipharm AB Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Recipharm AB Radiation Toxicity Therapeutics Product Portfolio Table 62. Recipharm AB Recent Development Table 63. Siegfried Holdings Company Information Table 64. Siegfried Holdings Business Overview Table 65. Siegfried Holdings Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Siegfried Holdings Radiation Toxicity Therapeutics Product Portfolio Table 67. Siegfried Holdings Recent Development Table 68. Viatris Company Information Table 69. Viatris Business Overview Table 70. Viatris Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Viatris Radiation Toxicity Therapeutics Product Portfolio Table 72. Viatris Recent Development Table 73. Amgen Company Information Table 74. Amgen Business Overview Table 75. Amgen Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Amgen Radiation Toxicity Therapeutics Product Portfolio Table 77. Amgen Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Radiation Toxicity Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novartis Radiation Toxicity Therapeutics Product Portfolio Table 82. Novartis Recent Development Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Radiation Toxicity Therapeutics Product Image Figure 2. Global Radiation Toxicity Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiation Toxicity Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Radiation Toxicity Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ionizing Radiation Image Figure 8. Non-ionizing Radiation Image Figure 9. Global Radiation Toxicity Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Radiation Toxicity Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Radiation Toxicity Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Research & Academic Institutes Image Figure 14. Global Radiation Toxicity Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Radiation Toxicity Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Radiation Toxicity Therapeutics Sales Value Share by Application (2021-2032) Figure 17. Global Radiation Toxicity Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Radiation Toxicity Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Radiation Toxicity Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 20. North America Radiation Toxicity Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Radiation Toxicity Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Radiation Toxicity Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Radiation Toxicity Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Radiation Toxicity Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Radiation Toxicity Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. South America Radiation Toxicity Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Radiation Toxicity Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Radiation Toxicity Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Ionizing Radiation
  • Non-ionizing Radiation
Applications
  • Hospital
  • Research & Academic Institutes
Companies covered
  • Coherus BioSciences
  • Jubilant Life Sciences
  • Mission Pharmacal Company
  • Partner Therapeutics
  • Recipharm AB
  • Siegfried Holdings
  • Viatris
  • Amgen
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Radiation Toxicity Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Radiation Toxicity Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Radiation Toxicity Therapeutics Market Dynamics
  1. 2.1 Radiation Toxicity Therapeutics Industry Trends
  2. 2.2 Radiation Toxicity Therapeutics Industry Drivers
  3. 2.3 Radiation Toxicity Therapeutics Industry Opportunities and Challenges
  4. 2.4 Radiation Toxicity Therapeutics Industry Restraints
3 Radiation Toxicity Therapeutics Market by Company
  1. 3.1 Global Radiation Toxicity Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Radiation Toxicity Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Radiation Toxicity Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Radiation Toxicity Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Radiation Toxicity Therapeutics Company Product Type and Application
  6. 3.6 Global Radiation Toxicity Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Radiation Toxicity Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Radiation Toxicity Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Radiation Toxicity Therapeutics Market by Type
  1. 4.1 Radiation Toxicity Therapeutics Type Introduction
  2. 4.1.1 Ionizing Radiation
  3. 4.1.2 Non-ionizing Radiation
  4. 4.2 Global Radiation Toxicity Therapeutics Sales Value by Type
  5. 4.2.1 Global Radiation Toxicity Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Radiation Toxicity Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Radiation Toxicity Therapeutics Sales Value Share by Type (2021-2032)
5 Radiation Toxicity Therapeutics Market by Application
  1. 5.1 Radiation Toxicity Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Research & Academic Institutes
  4. 5.2 Global Radiation Toxicity Therapeutics Sales Value by Application
  5. 5.2.1 Global Radiation Toxicity Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Radiation Toxicity Therapeutics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Radiation Toxicity Therapeutics Sales Value Share by Application (2021-2032)
6 Radiation Toxicity Therapeutics Regional Value Analysis
  1. 6.1 Global Radiation Toxicity Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiation Toxicity Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Radiation Toxicity Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Radiation Toxicity Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Radiation Toxicity Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Radiation Toxicity Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Radiation Toxicity Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Radiation Toxicity Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Radiation Toxicity Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Radiation Toxicity Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Radiation Toxicity Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Radiation Toxicity Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Radiation Toxicity Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Radiation Toxicity Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Radiation Toxicity Therapeutics Country-level Value Analysis
  1. 7.1 Global Radiation Toxicity Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Radiation Toxicity Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Radiation Toxicity Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Radiation Toxicity Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Radiation Toxicity Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Radiation Toxicity Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Radiation Toxicity Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Coherus BioSciences
  2. 8.1.1 Coherus BioSciences Company Information
  3. 8.1.2 Coherus BioSciences Business Overview
  4. 8.1.3 Coherus BioSciences Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Coherus BioSciences Radiation Toxicity Therapeutics Product Portfolio
  6. 8.1.5 Coherus BioSciences Recent Developments
  7. 8.2 Jubilant Life Sciences
  8. 8.2.1 Jubilant Life Sciences Company Information
  9. 8.2.2 Jubilant Life Sciences Business Overview
  10. 8.2.3 Jubilant Life Sciences Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Jubilant Life Sciences Radiation Toxicity Therapeutics Product Portfolio
  12. 8.2.5 Jubilant Life Sciences Recent Developments
  13. 8.3 Mission Pharmacal Company
  14. 8.3.1 Mission Pharmacal Company Company Information
  15. 8.3.2 Mission Pharmacal Company Business Overview
  16. 8.3.3 Mission Pharmacal Company Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mission Pharmacal Company Radiation Toxicity Therapeutics Product Portfolio
  18. 8.3.5 Mission Pharmacal Company Recent Developments
  19. 8.4 Partner Therapeutics
  20. 8.4.1 Partner Therapeutics Company Information
  21. 8.4.2 Partner Therapeutics Business Overview
  22. 8.4.3 Partner Therapeutics Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Partner Therapeutics Radiation Toxicity Therapeutics Product Portfolio
  24. 8.4.5 Partner Therapeutics Recent Developments
  25. 8.5 Recipharm AB
  26. 8.5.1 Recipharm AB Company Information
  27. 8.5.2 Recipharm AB Business Overview
  28. 8.5.3 Recipharm AB Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Recipharm AB Radiation Toxicity Therapeutics Product Portfolio
  30. 8.5.5 Recipharm AB Recent Developments
  31. 8.6 Siegfried Holdings
  32. 8.6.1 Siegfried Holdings Company Information
  33. 8.6.2 Siegfried Holdings Business Overview
  34. 8.6.3 Siegfried Holdings Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Siegfried Holdings Radiation Toxicity Therapeutics Product Portfolio
  36. 8.6.5 Siegfried Holdings Recent Developments
  37. 8.7 Viatris
  38. 8.7.1 Viatris Company Information
  39. 8.7.2 Viatris Business Overview
  40. 8.7.3 Viatris Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Viatris Radiation Toxicity Therapeutics Product Portfolio
  42. 8.7.5 Viatris Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Radiation Toxicity Therapeutics Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Radiation Toxicity Therapeutics Product Portfolio
  54. 8.9.5 Novartis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst